Our History

Nuclear Laser Medicine was founded in 1986. The company quickly establishes itself as a local distributor of diagnostic devices produced by various manufacturers, including Dupont, for which it developed the market for kits used in the detection of HIV virus infection. After one year of activity the range of products has been enlarged with the kits used in the detection of HCV virus infection.  

Only ten years after its foundation, Nuclear Laser Medicine was the first and only company in Italy to obtain registration of the rapid HIV test, "capillus HIV 1/2", approved by the ’ISTITUTO SUPERIORE DI SANITA’ (SUPERIOR INSTITUTE OF HEALTH)

During the nineties, the company signed important  distribution agreements with major international companies. These partnerships, together with the constant expansion of its own range of in-house produced kits, established the company as one of the leaders within the scope of IVD on the Italian market within only a few years. 

In 1997 the first activities of bottling and packaging were inaugurated and within a few months they were applied to the entire productive cycle.  A complete business reorganization followed, which then lead to the obtention of the ISO 9002:1994 / 1998 certification.

In 1999 the company begins the distribution in Italy of the first kit for the detection of 2nd generation hepatitis C, products from United Biotech and in 2000 implements the range of kits for genetic analysis on strip (Reverse Dot Blot) for cardiovascular pathologies,

 particularly to the mutations panel connected to the coagulative process. In 2001 a Research & development department was launched and the production of molecular biology for investigations of genetic type devices initiated. In 2003, after a 2  year long process, the update of ISO 9001:2000 and ISO 13485 standards were completed. At the same time, and in accordance with the terms defined at European levels, steps were taken to ensure conformity of the devices to the CE marking according to directive 98/79 EC (D.Lgs 332-2000) .

Subsequently in 2004, resulting from the membrane consolidation technology, the first strip test fully developed and produced in-house by Nuclear Laser Medicine is introduced on the market. By the following year the range of diagnostic on strip devices was gradually deployed and in 2006 the genetic test on strip for the diagnosis of Cystic Fibrosis, developed with the most important mutations present on the national territory, was introduced on the Italian market. Moreover, in the same year, the company started its expansion towards international markets and in particularly in Europe, the Middle East and Turkey.

Between 2007 and 2010 Real Time kits are introduced onto the market for the genetic investigations of the trombofilic panel and subsequently in 2012, completing that range, the Cardio-Kit (www.cardiokit-nlm.com), a new prognostic test on strip capable of determining a genetic predisposition to coronary artery disease is unveiled at the AACC of Los Angeles.

At the beginning of 2014, Nuclear Laser Medicine launched a new test for the genotyping of hepatitis C dual target, 5'UTR and CORE , developed following international guidelines. The kit consents to distinguish between the various subtypes and particularly between 1a and 1b. Finally, between 2014 and 2016, new genetic tests for the analysis of chromosomal Aneuploidy (AA 1302/25 - Cario 5 Type) were launched on the market, developed using the quantitative fluorescence polymerase chain reaction technique and cystic fibrosis (AA 1358/48 - CF FAST), developed with the fluorescent ARMS (Amplification Refractory Mutation Detection System) technology.

For the past thirty years, Nuclear Laser Medicine has always been an all Italian reality, leader on the italian, european and mediterranean Countries.





Nuclear Laser Medicine srl
Viale delle Industrie, 3 - 20090
Settala (MI) - ITALIA
Tel: +39 02 952451 - Fax: +39 02 95245238/37

P.Iva/Cod.Fisc.: 08763060152 - Cap. Soc. € 110.000,00 i.v.



Nuclear Laser Medicine srl is certified